Britain and America have concluded a major commercial pact that will maintain no duties on UK drug shipments going into the US market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has committed to raise spending on drugs through the NHS. This commitment secures that duties on these key exports will be held at nothing for a period of the next three years.
This development comes after previous warnings to significantly raise tariffs on patented drug products, with figures mentioned up to 100%.
"This deal between the UK strengthens the global environment for new treatments and establishes much-needed fairness to American-British medicine commerce," an announcement declared.
Commercial Impact
Pharmaceuticals constitute one of the Britain's largest goods shipped to the US, which is by far the biggest market for major companies like GSK and AstraZeneca.
Export figures show that in the one-year period prior to the third quarter, the UK exported drugs totaling £11.1bn to the US. This amount made up a significant portion of British export trade in that span.
"This deal protects employment, boosts investment and paves the way for the UK to establish itself as a worldwide center for biotech and pharma," a minister remarked.
Key NHS Changes
The pact entails several specific changes from the British government:
- Price Threshold Increase: The UK will increase the cost ceiling at which it deems new medicines to be too expensive by a quarter.
- Increased NHS Spending: There is a aim to increase total NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Rebate Cap: The sum drug companies must refund to the NHS to control costs will be capped at 15%. Previously, refunds exceeded twenty percent.
Industry Background
The pact comes amid a long-running dispute between the drug companies and the UK government over drug pricing and NHS adoption.
The disagreement were exacerbated by claims that American customers were paying a premium for the same drugs than patients in the UK and Europe.
In recent months, several major manufacturing plans in the UK have been delayed or abandoned, while major expansions have been announced toward US facilities.
The Science Minister stated that the NHS had to invest a greater share on drugs, noting that its budget allocation on drugs had decreased as a proportion of its total funding over the past decade.
